Commercially available molecular tests for human papillomaviruses (HPV): 2015 update

Poljak, Mario; Kocjan, Boštjan J.; Oštrbenk, Anja; Seme, Katja

doi:10.1016/j.jcv.2015.10.023

Cited by 114 publications

(103 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At this time, there are at least 193 distinct molecular tests that are commercially available on the global market for the detection of HPV in cervical specimens (124). Of the 193 available tests, 110 (57%) have a least one publication in peer-reviewed literature, but only 69 (35.7%) ae supported by published analytical and/or clinical evaluation (124).…”

Section: Hpv Molecular Detection Methodsmentioning

confidence: 99%

“…Of the 193 available tests, 110 (57%) have a least one publication in peer-reviewed literature, but only 69 (35.7%) ae supported by published analytical and/or clinical evaluation (124). Several of the available molecular tests have been approved by the FDA for use in the United States or clinically validated using the Meijer criteria for use in Europe and Canada (Table 5) (125,126).…”

Section: Hpv Molecular Detection Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Human Papillomavirus Laboratory Testing: the Changing Paradigm

2016

View full text Add to dashboard Cite

SUMMARYHigh-risk human papillomaviruses (HPVs) cause essentially all cervical cancers, most anal and oropharyngeal cancers, and some vaginal, vulvar, and penile cancers. Improved understanding of the pathogenesis of infection and the availability of newer tests are changing the approach to screening and diagnosis. Molecular tests to detect DNA from the most common high-risk HPVs are FDA approved for use in conjunction with cytology in cervical cancer screening programs. More-specific tests that detect RNA from high-risk HPV types are now also available. The use of molecular tests as the primary screening tests is being adopted in some areas. Genotyping to identify HPV16 and -18 has a recommended role in triaging patients for colposcopy who are high-risk HPV positive but have normal cytology. There are currently no recommended screening methods for anal, vulvar, vaginal, penile, or oropharyngeal HPV infections. HPV testing has limited utility in patients at high risk for anal cancer, but p16 immunohistochemistry is recommended to clarify lesions in tissue biopsy specimens that show moderate dysplasia or precancer mimics. HPV testing is recommended for oropharyngeal squamous cell tumors as a prognostic indicator. Ongoing research will help to improve the content of future guidelines for screening and diagnostic testing.

show abstract

Section: Hpv Molecular Detection Methodsmentioning

confidence: 99%

Section: Hpv Molecular Detection Methodsmentioning

confidence: 99%

Human Papillomavirus Laboratory Testing: the Changing Paradigm

2016

View full text Add to dashboard Cite

show abstract

“…The primary differences between genotyping assays are the target amplicon (gene region targeted, size of amplicon, primer sequence), detection probes, and amplicon detection method. A comprehensive description of these can be found in a recent review, 22 and examples of the most commonly used assay types are also shown in Table 1. The most common amplification targets for alpha papillomaviruses include the L1, E6, and E7 genes.…”

Section: Technical Issues Around Testing For Hpv-52mentioning

confidence: 99%

Technical Issues Associated With Estimating the Prevalence of HPV-52 in Cervical Intraepithelial Neoplasia

Cornall¹,

Plummer²,

Molano³

et al. 2017

ATV

View full text Add to dashboard Cite

“…More recently the research has translated into global primary and secondary disease prevention strategies, which increasingly depend on HPV-based vaccination and testing [4]. In synch with such developments, laboratory technologies have advanced dramatically; molecular detection strategies have ostensibly replaced “direct morphology-based identification” and themselves have evolved from straightforward detection of single target(s) via PCR into next-generation platforms with massive resolving power that can rapidly detect whole viral genomes and sequence the host genome which HPVs occupy [5, 6]. …”

Section: Introductionmentioning

confidence: 99%

Human Papillomavirus Research: Where Should We Place Our Bets?

2019

View full text Add to dashboard Cite

Background: Massive strides have been made with respect to primary and secondary prevention of human papillomavirus (HPV)-associated disease as a result of prophylactic vaccination and cervical screening based on molecular HPV testing. However, cervical cancer continues to be an important clinical and societal burden. Additionally, other HPV-associated cancers, for which there are no screening programmes, are rising. Finally, the optimal combination of vaccination and screening strategies will require careful thinking. Considering this unprecedented and important time, we were keen to solicit the views of the expert community to determine what they perceived were the key priorities for HPV research. Our objective was to identify consensus and key priorities for HPV-based research through provision of a questionnaire disseminated to a multidisciplinary group of key opinion leaders (KOLs). Summary: A structured survey composed of 46 HPV research “categories” was sent to 73 KOLs who were invited to “rank” the categories according to priority. The invitees represented clinical and public health disciplines as well as basic scientists. Scores were weighted according to the number of responses. Invitees also had the opportunity to comment on barriers to the research and suggest other research areas that required attention not reflected in the survey. We received 29 responses in total; overall, the 3 highest-ranked categories were “optimal cervical screening in low and middle-income countries (LMICs),” “primary disease prevention in LMICs” and “impact of vaccine on HPV infection and associated disease.” “HPV and the microbiome” and “mechanisms of transformation” were the highest-ranked categories with respect to basic research. Consistent barriers to research were around governance on the use of samples and data and funding, particularly in an era of vaccination. Key Messages: Research to support the management of disease in LMICs is clearly perceived as a priority in the international community in addition to other diverse areas which necessitate an improved basic understanding of viral mechanisms and interactions. International, multidisciplinary efforts which articulate the broader HPV research agenda will be important when seeking funding in addition to international endeavours to support the efficient use of existing samples and cohorts to facilitate such research.

show abstract

Commercially available molecular tests for human papillomaviruses (HPV): 2015 update

Cited by 114 publications

References 56 publications

Human Papillomavirus Laboratory Testing: the Changing Paradigm

Human Papillomavirus Laboratory Testing: the Changing Paradigm

Technical Issues Associated With Estimating the Prevalence of HPV-52 in Cervical Intraepithelial Neoplasia

Human Papillomavirus Research: Where Should We Place Our Bets?

Contact Info

Product

Resources

About